B+
Bull case
20%
Probability
Target price
$1.10
+56.9% vs current
TRIB
Trinity BiotechDNasdaq / Health Care Equipment & Services
Last Price
At close
2026-06-03
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.60
-14.4% vs current
B-
Bear case
35%
Probability
Target price
$0.30
-57.2% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-26.5
Negative
Company
-
Unavailable
Macro
-26.5
Negative
Pulse
-
Unavailable
Sentiment proxy
+32.0
Score
AI commentary
Lean monitoring view. Deterministic priors are mildly negative and evidence quality in the packet was effectively zero, so the memo should stay cautious. Primary sources confirm a real turnaround narrative and real CGM progress, but they also confirm listing and balance-sheet fragility. The setup is best viewed as distressed optionality rather than a high-conviction directional long.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-08-18catalystNasdaq MVPHS compliance clock remains an overhang [#PR-2026-02-20]High impact
The company said on February 20, 2026 that Nasdaq notified it TRIB no longer met the $15 million minimum market value of publicly held shares requirement, with until August 18, 2026 to regain compliance or seek transfer to Nasdaq Capital Market. For a ~$14 million market cap name, this listing-status overhang can dominate near-term trading.
2026-09-30catalystDiagnostics turnaround must prove durable cash generation beyond restructuring claims [#20F-2024]High impact
The 2024 Form 20-F reported a $31.8 million annual loss, $5.2 million of cash and deposits, and negative total equity, while also stating restructuring actions were expected to deliver meaningful savings and that further liquidity levers included deferring R&D spend. The July 1, 2025 update said the company expected adjusted EBITDA positivity and operating cash-flow positivity from Q3 2025, so the long debate is whether core diagnostics and HIV/HbA1c rollout can sustain liquidity without repeated balance-sheet stress.
2026-12-31eventCGM+ development updates need to convert into dated pivotal-trial or regulatory proof [#PR-2026-03-10]High impact
Management said on March 10, 2026 that recent technical gains gave it strong conviction to accelerate into pivotal trials in 2026. Earlier company releases also framed CGM as the largest-scale growth opportunity, but the packet lacks third-party confirmation or a filed regulatory milestone, so this remains a proof-of-execution watch item rather than a clean upside trigger.
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology